Recent News

• 04.17.2025 - bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
• 03.31.2025 - bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
• 03.26.2025 - Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
• 03.19.2025 - Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
• 03.13.2025 - Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
• 03.06.2025 - bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
• 02.26.2025 - bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
• 02.25.2025 - bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Recent Filings

• 04.15.2025 - PRE 14A Other preliminary proxy statements
• 04.14.2025 - 8-K Current report
• 04.11.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.07.2025 - 8-K Current report
• 03.07.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 8-K Current report
• 02.27.2025 - EX-99.1 EX-99.1